Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deldeprevir SCHEMBL16020696 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| Deldeprevir SCHEMBL13291708 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| Deldeprevir SCHEMBL16020697 | 1.00 | CTSS (0.67) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL25524203 | 0.96 | CTSS (0.60) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927407 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13291725 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927409 | 0.95 | CTSS (0.72) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927450 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL13291731 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB | |
| SCHEMBL16927447 | 0.94 | CTSS (0.68) | CTSSADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3448392-B1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Atea Pharmaceuticals, Inc. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4346772-B1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4132651-B1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS | GILEAD SCIENCES INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-03-03 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11318119-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220072021-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022046631-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3955921-A1 | 2-IMINO-5-OXO-IMIDAZOLIDINE INHIBITORS OF HIV PROTEASE | GILEAD SCIENCES, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CTSS 1005/4885ADRB3 3789/4885ADRA2B 4205/4885 |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CTSS 3714/4885ADRB3 660/4885ADRA2B 864/4885 |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | CTSS 2914/4885ADRB3 1888/4885ADRA2B 3125/4885 |
| US-12565665-B2 | Compositions and methods for controlled mRNA translation and stability | ADAR, ADA, NSUN2 | CTSS 4768/4885ADRB3 3872/4885ADRA2B 3039/4885 |
| US-11318119-B2 | HIV protease inhibitors | ACE, PRSS1, TMPRSS2 | CTSS 12/4885ADRB3 3983/4885ADRA2B 4619/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | CTSS 53/4885ADRB3 3737/4885ADRA2B 3371/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | CTSS 3269/4885ADRB3 1698/4885ADRA2B 2945/4885 |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CTSS 951/4885ADRB3 3857/4885ADRA2B 4281/4885 |
| US-20220072021-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | EIF2AK2, SARS1, ZC3HAV1 | CTSS 103/4885ADRB3 3055/4885ADRA2B 2858/4885 |
| US-20260091050-A1 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | SLC10A1, SLC10A2, STAT3 | CTSS 846/4885ADRB3 3229/4885ADRA2B 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.